ARTICLE 1 DEFINITIONSCollaborative Research and License Agreement • April 26th, 2002 • Cardiome Pharma Corp • Pharmaceutical preparations • Quebec
AMENDED AND RESTATED COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between TARGACEPT, INC. and AVENTIS PHARMA SACollaborative Research and License Agreement • January 17th, 2006 • Targacept Inc • Pharmaceutical preparations • New York
This Amended and Restated Collaborative Research and License Agreement (this “Agreement”) is made and entered into as of January 21, 2002, by and between Targacept, Inc., a Delaware corporation having its principal place of business at 950 Reynolds Boulevard, Winston-Salem, North Carolina 27105 (“Targacept”), and Aventis Pharma SA, a corporation organized and existing under the laws of France having its principal place of business at 20, avenue Raymond Aron, 92160 Antony, France (“APSA”) (each of Targacept and APSA a “Party” and collectively, the “Parties”).
BACKGROUNDCollaborative Research and License Agreement • November 17th, 1999 • Symyx Technologies Inc • Services-commercial physical & biological research • Delaware
1. DEFINITIONS -----------Collaborative Research and License Agreement • September 2nd, 1997 • Siga Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
EX-10.19 21 d386058dex1019.htm COLLABORATIVE RESEARCH AND LICENSE AGREEMENT Execution Copy COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between WARNER CHILCOTT COMPANY, INC. and PARATEK PHARMACEUTICALS, INC. July 2, 2007Collaborative Research and License Agreement • May 5th, 2020 • New York
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT by and between TARGACEPT, INC. and ASTRAZENECA AB December 27, 2005Collaborative Research and License Agreement • May 26th, 2006 • Targacept Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 27, 2005 (the “Execution Date”), by and between Targacept, Inc., a Delaware corporation having an address of 200 East First Street, Suite 300, Winston-Salem, NC 27101-4165 (“Targacept”), and AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden, having its principal place of business at V-Malarehamnen 9, S-151 85 Södertälje, Sweden (“AstraZeneca”), effective as of the Effective Date, except for those provisions that are expressly stated to be effective as of the Execution Date, which shall be effective as of the Execution Date. Each of AstraZeneca and Targacept is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
EXHIBIT 10.23 COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • June 17th, 1997 • Aurora Biosciences Corp • Services-commercial physical & biological research • California
EXHIBIT 10.18 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT This Collaborative Research and License Agreement is made and effective as of October 18, 1999 (the "Effective Date"), by and between 3-Dimensional Pharmaceuticals, Inc., a corporation having...Collaborative Research and License Agreement • July 28th, 2000 • 3 Dimensional Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • January 14th, 2005 • Icagen Inc • Pharmaceutical preparations • New York
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) dated as of September , 1997 is between ICAgen Inc., a corporation duly organized and existing under the laws of the State of Delaware, and having offices at 4222 Emperor Boulevard, Suite 460, Durham, North Carolina 27703 (“ICAgen”) and Bristol-Myers Squibb Company, a corporation duly organized and existing under the laws of the state of Delaware, having offices at P.O. Box 4000, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, for and on behalf of itself and its Affiliates (“BMS”).
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between ARCHEMIX CORP. and MERCK KGaA June 6, 2007Collaborative Research and License Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 6, 2007, by and between Archemix Corp., a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“ARCHEMIX”), and Merck KGaA, a company organized under the laws of Germany with offices at Frankfurter Str. 250, 64293 Darmstadt, Germany (“MERCK”). Each of MERCK and ARCHEMIX is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • June 9th, 2004 • Senomyx Inc • Services-commercial physical & biological research • California
THIS AGREEMENT is entered into as of the Effective Date by and between SENOMYX, INC., a Delaware Corporation having offices at 11099 North Torrey Pines Road, La Jolla, CA 92037 ("Senomyx") and KRAFT FOODS, INC., a Delaware Corporation having offices at 801 Waukegan Road, Glenview, IL 60025 ("Kraft").
LOGO APPEARS HERE] J. Donald deBethizy, Ph.D. President and CEOCollaborative Research and License Agreement • January 17th, 2006 • Targacept Inc • Pharmaceutical preparations
Reference is hereby made to that certain: (a) Amended and Restated Collaborative Research and License Agreement made and entered into as of January 21, 2002 (the “First Agreement”) by and between Targacept, Inc. (“Targacept”) and Aventis Pharma SA (“Aventis”) and (b) Collaborative Research and License Agreement made and entered into as of January 21,2002 by and between Targacept and Aventis (the “Second Agreement” and, together with the First Agreement, the “Agreements”).
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BY AND BETWEEN NOILE-IMMUNE BIOTECH, INC. AND LEGEND BIOTECH USA, INC. April 27, 2020Collaborative Research and License Agreement • May 29th, 2020 • Legend Biotech Corp • Pharmaceutical preparations
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is made as of April __, 2020 (the “Effective Date”) by and between Noile-Immune Biotech, Inc., a Japanese corporation having its principal place of business at 2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan (“Noile”), and Legend Biotech USA, Inc., a company incorporated under the laws of New York having its principal place of business at 10 Knightsbridge Road, Piscataway, NJ 08854, USA (“Legend”). Noile and Legend are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • June 9th, 2004 • Senomyx Inc • Services-commercial physical & biological research • California
THIS AGREEMENT is entered into as of the Effective Date by and between SENOMYX, INC., a Delaware corporation having offices at 11099 North Torrey Pines Road, La Jolla, California 92037 ("Senomyx"), and AURORA BIOSCIENCES CORPORATION, a Delaware corporation having offices at 11010 Torreyana Road, San Diego, California 92121 ("Aurora").
EX-10.30 2 d507480dex1030.htm EX-10.30 CONFIDENTIAL ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under Contract number: [***] COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between...Collaborative Research and License Agreement • May 5th, 2020
WHEREAS BOEHRINGER is a research-based pharmaceutical company and is interested in a research program related to DICERNA’s proprietary GalXC technology which enables precise silencing of disease-driving genes in the liver, specifically targeting the hepatocyte.
EX-10.1 2 dex101.htm AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • May 5th, 2020
This Amendment No. 1 to Collaborative Research and License Agreement (this “Amendment”), dated November 10, 2006, amends the Collaborative Research and License Agreement entered into as of December 27, 2005 (the “Agreement”) by and between AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden (“AstraZeneca”), and Targacept, Inc., a Delaware (USA) corporation (“Targacept”).
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between ARCHEMIX CORP. and TAKEDA PHARMACEUTICAL COMPANY LIMITED June 11, 2007Collaborative Research and License Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 11, 2007, by and between Archemix Corp., a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“ARCHEMIX”), and Takeda Pharmaceutical Company Limited, a Japanese corporation with a principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“TAKEDA”). Each of TAKEDA and ARCHEMIX is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
RECITALSCollaborative Research and License Agreement • August 10th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between ARCHEMIX CORP. and ELAN PHARMA INTERNATIONAL, LIMITED June 30, 2006Collaborative Research and License Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • Delaware
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 30, 2006, by and between Archemix Corp., a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“ARCHEMIX”), and Elan Pharma International Limited, a private company limited by shares organized under the laws of Ireland with offices at Monksland, Athlone, County Westmeath, Ireland (“ELAN”). Each of ELAN and ARCHEMIX is sometimes referred to individually herein as a “Party” and are sometimes referred to collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN ICAGEN INC. YAMANOUCHI PHARMACEUTICAL CO., LTD. DATED AS OF MARCH 21, 2000Collaborative Research and License Agreement • January 14th, 2005 • Icagen Inc • Pharmaceutical preparations • North Carolina
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) dated as of March 21, 2000 (the “Effective Date”) is entered into by and between ICAgen Inc., a corporation duly organized and existing under the laws of the State of Delaware and having offices at 4222 Emperor Boulevard, Suite 460, Durham, North Carolina 27703 (“ICAgen”), and Yamanouchi Pharmaceutical Co., Ltd., a corporation duly organized and existing under the laws of Japan and having offices at 3-11 NihonbashiHoncho 2-chome, Chuo-ku, Tokyo 103-8411, Japan (“YAMANOUCHI”).
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between TARGACEPT, INC. and AVENTIS PHARMA SACollaborative Research and License Agreement • January 17th, 2006 • Targacept Inc • Pharmaceutical preparations • Delaware
This Collaborative Research and License Agreement (this “Agreement”) is made and entered into as of January 21, 2002 (the “Effective Date”), by and between Targacept, Inc., a Delaware corporation having its principal place of business at 950 Reynolds Boulevard, Winston-Salem, North Carolina 27105 (“Targacept”), and Aventis Pharma SA, a corporation organized and existing under the laws of France having its principal place of business at 20, avenue Raymond Aron, 92160 Antony, France (“Aventis”). Each of Targacept and Aventis may be referred to individually herein as a “Party” and together as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between ARCHEMIX CORP. and MERCK, KGaA January 17, 2007Collaborative Research and License Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of January 17, 2007, by and between Archemix Corp., a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“ARCHEMIX”), and Merck KGaA, a company organized under the laws of Germany with offices at Frankfurter Str. 250, 64293 Darmstadt, Germany (“MERCK”). Each of MERCK and ARCHEMIX is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT July 10, 2009Collaborative Research and License Agreement • April 5th, 2010 • Codexis Inc • Industrial organic chemicals • New York
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT, together with schedules attached hereto (this “Agreement”) is entered into and effective as of July 10, 2009 (the “Effective Date”) by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063, United States of America, (“Codexis”), Iogen Energy Corporation, a corporation existing under the law of Canada, having a place of business at 310 Hunt Club Road East, Ottawa, Ontario K1V 1C1, Canada, (“IE”), Equilon Enterprises LLC dba Shell Oil Products US, a Delaware limited liability company, having a place of business at 910 Louisiana Street, Houston, Texas 77002, (“Shell US”), and Shell Chemicals Canada Limited, a corporation existing under the laws of Canada, having a place of business at 400 - 4th Avenue S.W., P.O. Box 4280, Station ‘C’, Calgary, Alberta T2T 5Z5, Canada (“Shell Canada” and together with Shell US “Shell”). Codexis, IE, Shell US and Shell Canada may
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN BIOGEN MA INC. AND C4 THERAPEUTICS, INC. Dated December 28, 2018Collaborative Research and License Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 28, 2018 (the “Effective Date”) by and among Biogen MA Inc., a corporation organized and existing under the laws of Massachusetts and having a principal place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”) and C4 Therapeutics, Inc., a corporation organized and existing under the laws of Delaware with a principle place of business at 490 Arsenal Way, Watertown, MA 02472 (“C4”). Biogen and C4 are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
BETWEENCollaborative Research and License Agreement • February 18th, 2000 • Signal Pharmaceuticals Inc • Services-commercial physical & biological research • California
THIRD AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • November 2nd, 2005 • Senomyx Inc • Services-commercial physical & biological research • California
THIS THIRD AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “Third Amendment”) is made by and between SENOMYX, INC. (“Senomyx”), a Delaware corporation, having a principal place of business at 11099 North Torrey Pines Road, La Jolla, California 92037, and KRAFT FOODS GLOBAL, INC., a Delaware corporation (“Kraft”) having offices at 801 Waukegan Road, Glenview, IL 60025.
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • April 14th, 2004 • Senomyx Inc • Services-commercial physical & biological research • California
This Agreement is entered into as of the Effective Date by and between Senomyx, Inc., a Delaware Corporation having offices at 11099 North Torrey Pines Road, La Jolla, CA 92037 ("Senomyx") and NESTEC, Ltd., a Swiss company, having its principal place of business at Avenue Nestlé 55, CH-1800 Vevey, Switzerland ("Nestlé").
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between Alexion Pharma Holding Unlimited Company Dicerna Pharmaceuticals Inc. and Dicerna Cayman DATED OCTOBER 22, 2018Collaborative Research and License Agreement • March 13th, 2019 • Dicerna Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 22, 2018 (the “Effective Date”) by and among ALEXION PHARMA HOLDING UNLIMITED COMPANY, an unlimited liability company incorporated under the laws of Ireland with a principal place of business at [***] (“ALEXION”), DICERNA PHARMACEUTICALS INC., a corporation organized and existing under the laws of Delaware with a principal place of business at 87 Cambridgepark Drive, Cambridge, MA 02140 (“DICERNA PHARMA”), and Dicerna Cayman, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“DICERNA CAYMAN”, and together with DICERNA PHARMA, “DICERNA”). ALEXION and DICERNA are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
FOURTH AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN SENOMYX AND CAMPBELLCollaborative Research and License Agreement • May 5th, 2006 • Senomyx Inc • Services-commercial physical & biological research • California
THIS FOURTH AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “Fourth Amendment”) is made by and between Senomyx, Inc. (“Senomyx”), a Delaware corporation, having a principal place of business at 11099 North Torrey Pines Road, La Jolla, CA 92037, and Campbell Soup Company (“Campbell”), having its principal place of business at Campbell Place, Camden, NJ 08103-1799.
SIXTH AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • November 2nd, 2007 • Senomyx Inc • Services-commercial physical & biological research • California
THIS SIXTH AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “Sixth Amendment”) is entered into as of July 18, 2007 (the “Sixth Amendment Effective Date”) by and between SENOMYX, INC. (“Senomyx”), a Delaware corporation, having a principal place of business at 4767 Nexus Centre Drive, San Diego, California 92121, and KRAFT FOODS GLOBAL, INC., a Delaware corporation (“Kraft”) having offices at 801 Waukegan Road, Glenview, IL 60025.
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • May 17th, 1999 • Aurora Biosciences Corp • Services-commercial physical & biological research • Aurora
CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY [********], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED....Collaborative Research and License Agreement • March 14th, 2014 • Targacept Inc • Pharmaceutical preparations
This Amendment No. 6 to Collaborative Research and License Agreement (this “Amendment”), effective as of the date of signature of the last Party to sign below, amends the Collaborative Research and License Agreement entered into as of December 27, 2005 by and between AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden (“AstraZeneca”), and Targacept, Inc., a Delaware (USA) corporation (“Targacept”), as amended by Amendment No. 1 dated November 10, 2006, Amendment No. 2 effective July 8, 2009, Amendment No. 3 effective April 30, 2010, Amendment No. 4 effective September 28, 2010 and Amendment No. 5 effective March 5, 2013 (the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Agreement.
ContractCollaborative Research and License Agreement • May 5th, 2020 • New York
<DOCUMENT> <TYPE>EX-10.7 <SEQUENCE>16 <FILENAME>a2025040zex-10_7.txt <DESCRIPTION>EX 10.7 <TEXT> <PAGE> EXHIBIT 10.7 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT ("the Agreement") is entered into as of January 31, 1999 ("Effective Date") by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017-5755 ("Pfizer") and RIGEL PHARMACEUTICALS, INC., a Delaware corporation, having an address at 772 Lucerne Drive, Sunnyvale, California 94086 ("Rigel"). Pfizer and Rigel and their Affiliates may be referred to herein individually as a "Party" or collectively as the "Parties." WHEREAS, Rigel has the capability and expertise to undertake research for the discovery of novel and selective elements of the IL-4 signaling pathway involved in the modulation of IgE synthesis that are suitable targets for an IgE synthesis-inhibitor, lead identification program; WHEREAS, Rigel owns the patents, pate
EX-10.13 2 d273854dex1013.htm AMENDED AND RESTATED COLLABORATIVE RESEARCH AND LICENSE AGREEMENT CONFIDENTIAL TREATMENT REQUESTED Final Execution Version AMENDED AND RESTATED COLLABORATIVE RESEARCH AND LICENSE AGREEMENT By and Among pSivida Corp....Collaborative Research and License Agreement • May 5th, 2020 • New York
This Amended and Restated Collaborative Research and License Agreement (the “Agreement”), dated as of June 14, 2011 (the “Effective Date”), is made by and among pSivida Corp., a Delaware corporation with offices located at 400 Pleasant Street, Watertown, Massachusetts, 02472, pSivida US, Inc., a Delaware corporation with offices located at 400 Pleasant Street, Watertown, Massachusetts 02472, pSiMedica Limited, a United Kingdom limited company with offices located at Malvern Hills Science Park, Geraldine Road, Malvern, Worcestershire, WR14 3SZ (collectively, “PSIVIDA”) and Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York, 10017 (“PFIZER”). PSIVIDA and PFIZER are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIFTH AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN SENOMYX AND CAMPBELLCollaborative Research and License Agreement • May 7th, 2009 • Senomyx Inc • Services-commercial physical & biological research • California
This Fifth Amendment (the “Fifth Amendment”) is entered into as of March 27, 2009 (the “Fifth Amendment Effective Date”), by and between Senomyx, Inc. (“Senomyx”) and Campbell Soup Company (“Campbell”).
